Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| LinkDoc Technology (Beijing) Co. Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The trial was designed to compare the effectiveness of radical resections of lung cancer plus adjuvant chemotherapies and perioperative chemotherapies in the patients with N2 non-small cell lung cancer
The trial is a multi-centre real-world non-interventional observational study. The Chinese patients with N2 non-small cell lung cancer enrolled from 2014 to 2017 who received radical resections of lung cancer and adjuvant chemotherapies will be included in the study and the study data on patient demographic/tumor biological characteristics and clinical treatment will be collected to evaluate compare effectiveness of radical resection of lung cancer plus adjuvant chemotherapies and perioperative chemotherapies after surgeries.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Surgeries+adjuvant chemotherapies | Patients who received radical resection of lung cancer + adjuvant chemotherapies |
| |
| Perioperative chemotherapies | Patients who received perioperative chemotherapies |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Surgeries | Procedure | Surgeries plus adjuvant chemotherapies or perioperative chemotherapies |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | Overall survival | 2014 - 2017 |
| Measure | Description | Time Frame |
|---|---|---|
| Disease-free survival | Disease-free survival | 2014 - 2017 |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survivals in the subgroups | Overall survivals in the subgroups categorized by T staging | 2014 - 2017 |
| Disease-free survivals in the subgroups | Disease-free survivals in the subgroups categorized by T staging |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Pathologically diagnosed Chinese patients with N2 non-small cell lung cancer who received radical resection of lung cancer plus adjuvant chemotherapies and perioperative chemotherapies
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| China-Japan Friendship Hospital | Beijing | Beijing Municipality | 100029 | China | ||
| China PLA General Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 2014 - 2017 |
| Impact factors of overall survival as measured by age | Impact factors of overall survival as measured by age | 2014 - 2017 |
| Impact factors of overall survival as measured by gender | Impact factors of overall survival as measured by gender | 2014 - 2017 |
| Impact factors of overall survival as measured by BMI | Impact factors of overall survival as measured by BMI | 2014 - 2017 |
| Impact factors of overall survival as measured by tumor size | Impact factors of overall survival as measured by tumor size | 2014 - 2017 |
| Impact factors of overall survival as measured by tumor location | Impact factors of overall survival as measured by tumor location | 2014 - 2017 |
| Impact factors of overall survival as measured by T staging | Impact factors of overall survival as measured by T staging | 2014 - 2017 |
| Impact factors of overall survival as measured by clinical treatments | Impact factors of overall survival as measured by surgeries plus adjuvant chemotherapies and surgeries plus perioperative chemotherapies | 2014 - 2017 |
| Time to local recurrence | Time to local recurrence | 2014 - 2017 |
| Time to distant recurrence | Time to distant recurrence | 2014 - 2017 |
| Death rate within 30/90 days after surgeries | Death rate within 30/90 days after surgeries | 2014 - 2017 |
| Impact factors of death rate within 30/90 days after surgeries as measured by patient demographic characteristics | Impact factors of death rate within 30/90 days after surgeries as measured by patient demographic characteristics | 2014 - 2017 |
| Impact factors of death rate within 30/90 days after surgeries as measured by tumor biological characteristics | Impact factors of death rate within 30/90 days after surgeries as measured by tumor biological characteristics | 2014 - 2017 |
| Impact factors of death rate within 30/90 days after surgeries as measured by various modes of surgeries | Impact factors of death rate within 30/90 days after surgeries as measured by various modes of surgeries | 2014 - 2017 |
| Incidence of perioperative complications | Incidence of perioperative complications | 2014 - 2017 |
| Beijing |
| Beijing Municipality |
| 100853 |
| China |
| Henan cancer hospital | Zhengzhou | Henan | 450008 | China |
| Tongji Hospital Affiliated to Huazhong Technology Hospital | Wuhan | Hubei | 430030 | China |
| Jiangsu cancer hospital | Nanjing | Jiangsu | 210009 | China |
| Xi'an Tangdu Hospital | Xi'an | Shaanxi | 710000 | China |
| Shanghai Chest Hospital | Shanghai | Shanghai Municipality | 200003 | China |
| Huaxi Hospital Affiliated to Sichuan University | Chengdu | Sichuan | 610041 | China |
| Tianjin Chest Hospital | Tianjin | Tianjin Municipality | 300051 | China |
| First Hospital Affiliated to Zhejiang University | Hangzhou | Zhejiang | 310003 | China |
| D013899 |
| Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |